MedTrace Logo

Total-body 13N-NH3 PET/CT to Study the Blood Perfusion in Severe AS Patients Pre- and Post-TAVR in Whole Body

NCT04941248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2026-03-17

No results posted yet for this study

Summary

The aim of our study is to analyze and quantitate whole-body blood perfusion by total-body 13N-NH3 PET/CT(uEXPLORER), and evaluate the influence to other organs in severe AS patients and the impact of TAVR surgery.

Conditions

  • Cardiac Output

Interventions

DEVICE

total-body PET/CT(uEXPLORER , United Imaging Healthcare, China)

This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function . All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Yumei Chen, Ph.D; M.D. · RenJi Hospital

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-27
Primary Completion
2026-01-08
Completion
2026-02-08
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04941248 on ClinicalTrials.gov